Comparing the current results to its competitors, Biolinerx Ltd reported Revenue decrease in the 4 quarter 2025 year on year by -95.92 %, despite the revenue increase by the most of its competitors of 3.86 %, recorded in the same quarter.
Biolinerx Ltd 's Comment on Competition and Industry Peers
The company faces competition from therapeutics that may be more effective, safer, or less expensive than its candidates, including GLIX1 and motixafortide. Market acceptance of these products depends on factors such as advantages over competing therapies, the number of approved competitors for similar indications, marketing effectiveness, inclusion in treatment guidelines, side effect profiles, efficacy, safety, reimbursement competitiveness, tolerability, and willingness of patients and physicians to use the products. Collaborators may maintain relationships with other commercial entities that compete with the company, which could negatively impact its competitive position. The company depends on third-party manufacturers and data providers, and any failure by these parties could adversely affect product development and marketing efforts. Additionally, the company faces challenges from standard of care treatments involving stem cell mobilization and generic versions such as APHEXDA, which require substantial resources to educate the medical community and payors.
Akero Therapeutics Inc is a biotechnology company that focuses on the development of breakthrough treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders. Their business model revolves around advancing their proprietary drug candidates through preclinical and clinical stages to ultimately bring them to market, partnering with leading academic institutions and leveraging scientific expertise to drive innovation in the field. Akero Therapeutics aims to address the significant unmet medical needs in these areas and create value for patients, healthcare providers, and shareholders.
Cue Biopharma Inc is a biopharmaceutical company that focuses on developing a novel class of medicines called Immuno-STATs. Their business model involves utilizing the body's immune system to target and treat a wide range of diseases, including cancer, autoimmune disorders, and viral infections. They collaborate with strategic partners and employ their expertise in immunology, protein engineering, and synthetic biology to develop these innovative therapies.
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Hutchmed China Limited operates on a vertically integrated platform, focusing on the discovery, development, and commercialization of targeted therapeutics for oncology and immunological diseases. The company employs a comprehensive business model that encompasses research and development, manufacturing, marketing, and sales in order to deliver innovative drugs to patients. By leveraging its internal capabilities and strategic partnerships, Hutchmed China aims to transform the treatment landscape and improve the lives of patients in China and around the world.
Immuneering Corp operates on a business model that harnesses the power of big data in the field of biomedicine. Through their proprietary technologies, they analyze vast amounts of biological data to gain insights into disease mechanisms, drug discovery, and patient care. They leverage their expertise to provide pharmaceutical companies and healthcare organizations with actionable information for accelerating the development of new therapeutics and improving clinical outcomes.
Sources:
Biolinerx Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Biolinerx Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
